<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05617469</url>
  </required_header>
  <id_info>
    <org_study_id>AICT-01</org_study_id>
    <nct_id>NCT05617469</nct_id>
  </id_info>
  <brief_title>DLCS for Predicting Neoadjuvant Chemotherapy Response</brief_title>
  <official_title>Deep Learning Radio-clinical Signatures for Predicting Neoadjuvant Chemotherapy Response and Prognosis From Pretreatment CT Images of LAGC Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The early noninvasive screening of patients suitable for neoadjuvant chemotherapy (NCT) is&#xD;
      essential for personalized treatment in locally advanced gastric cancer (LAGC). The aim of&#xD;
      this study was to develop and visualized a radio-clinical biomarker from pretreatment&#xD;
      oversampled CT images to predict the response and prognosis to NCT in LAGC patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2022</start_date>
  <completion_date type="Anticipated">July 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor regression grade</measure>
    <time_frame>3 months</time_frame>
    <description>Tumor regression grade</description>
  </primary_outcome>
  <enrollment type="Anticipated">1100</enrollment>
  <condition>Gastric Cancer</condition>
  <condition>CT Images</condition>
  <condition>Deep Learning</condition>
  <condition>Neoadjuvant Chemotherapy</condition>
  <condition>Tumor Regression Grade</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>develop and visualized a radio-clinical signatures from pretreatment oversampled CT images</intervention_name>
    <description>develop and visualized a radio-clinical signatures from pretreatment oversampled CT images to predict the neoadjuvant chemotherapy response and prognosis</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        patients with histologically confirmed GC/esophagogastric junction cancer (EGJC) who&#xD;
        received NCT prior to surgical resection&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1) patients with GC/EGJC confirmed by pathological examination; 2) patients who underwent&#xD;
        D2 lymphadenectomy; 3) patients who received at least two cycles of preoperative&#xD;
        chemotherapy; 4) patients with negative resection margins; and 5) patients with complete CT&#xD;
        image data and clinical data.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1) patients unable to undergo D2 radical gastrectomy after neoadjuvant therapy; and 2)&#xD;
        patients with incomplete CT images and clinical data.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital)</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangdong Cheng, MD</last_name>
      <phone>+0086-0571-88128041</phone>
      <email>Chengxd516@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 8, 2022</study_first_submitted>
  <study_first_submitted_qc>November 8, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>November 8, 2022</last_update_submitted>
  <last_update_submitted_qc>November 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Zhejiang Cancer Hospital</investigator_affiliation>
    <investigator_full_name>Xiangdong Cheng</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Due to the privacy of patients, the data related to patients cannot be available for public access but can be obtained from the corresponding author on reasonable request approved by the institutional review board of all enrolled centers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

